TG Therapeutics, Inc. (TGTX) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$43.02
Price Target
$39.00
Target Range
$39.00 — $39.00
Analyst Rating
Buy
Forward P/E32.3x
Trailing P/E15.5x
Forward PEG—
Implied Growth-53.8%
Median Target$39.00
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$39
-9.4%
Consensus
$39
-9.4%
Bull Case
$39
-9.4%
TGTX Price Target Analysis
Updated May 8, 2026As of May 8, 2026, TG Therapeutics, Inc. (TGTX) has a Wall Street consensus price target of $39.00, based on estimates from 13 covering analysts. With the stock currently trading at $43.02, this represents a potential downside of -9.4%. The company has a market capitalization of $6.87B.
Analyst price targets range from a low of $39.00 to a high of $39.00, representing a 0% spread in expectations. The median target of $39.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TGTX trades at a trailing P/E of 15.5x and forward P/E of 32.3x. Analysts expect EPS to grow -53.8% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+31.4%
Avg Forward P/E15.7x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RCUSArcus Biosciences, Inc. | $2.5B | $24.80 | $30.00 | +21.0% | Buy | — | 18 |
 IMVTImmunovant, Inc. | $5.5B | $27.22 | $45.50 | +67.2% | Buy | — | 23 |
 PRAXPraxis Precision Medicines, Inc. | $9.6B | $333.28 | $544.40 | +63.3% | Buy | — | 16 |
 KYMRKymera Therapeutics, Inc. | $6.9B | $84.63 | $117.06 | +38.3% | Buy | — | 26 |
 VRTXVertex Pharmaceuticals Incorporated | $108.1B | $425.00 | $552.27 | +29.9% | Buy | 22.2x | 56 |
 ALKSAlkermes plc | $5.9B | $35.40 | $44.00 | +24.3% | Buy | — | 28 |
 BIIBBiogen Inc. | $28.3B | $191.38 | $211.42 | +10.5% | Buy | 13.0x | 48 |
 GILDGilead Sciences, Inc. | $166.4B | $134.06 | $161.88 | +20.8% | Buy | 15.7x | 58 |
 ABBVAbbVie Inc. | $358.4B | $202.64 | $256.64 | +26.6% | Buy | 14.3x | 41 |
 INCYIncyte Corporation | $19.5B | $97.77 | $109.50 | +12.0% | Buy | 13.1x | 44 |
Upside Potential Comparison
IMVTPRAXKYMRVRTXABBVALKSRCUSGILDSee TGTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TGTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TGTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTGTX — Frequently Asked Questions
Quick answers to the most common questions about buying TGTX stock.
What is the TGTX stock price target for 2026?
Wall Street's consensus price target for TGTX is $39, -9.4% from its current price of $43.025. The below-market target from 13 analysts suggests limited near-term appreciation.
Is TGTX a buy, sell, or hold?
TGTX has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $39 implies -9.4% downside from current levels.
Is TGTX stock overvalued or undervalued?
TGTX trades at a forward P/E of 32.2502x, representing a moderate valuation. With analysts targeting $39 (-9.4% implied move), the stock appears close to fair value.
How high can TGTX stock go?
The most bullish Wall Street analyst has a price target of $39 for TGTX, while the most conservative target is $39. The consensus of $39 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover TGTX stock?
TGTX is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 1 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the TGTX stock forecast?
The 12-month TGTX stock forecast based on 13 Wall Street analysts shows a consensus price target of $39, with estimates ranging from $39 (bear case) to $39 (bull case). The median consensus rating is "Buy".
What is TGTX's forward P/E ratio?
TGTX trades at a forward P/E ratio of 32.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 15.5x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy TGTX stock?
Analysts are cautious on TGTX, with 1 Sell ratings and a price target of $39 (-9.4% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do TGTX price targets vary so much?
TGTX analyst price targets range from $39 to $39, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $39 consensus represents the middle ground.